研究组长

金浩杰，研究员，课题组长，博士生导师。

研究方向

1. 肝胆肿瘤靶向治疗新策略探索；

2. 抗肿瘤联合疗法的临床转化研究；

3. 肿瘤靶免治疗副作用机制及干预策略研究。

代表性论文

1. Zhen Sun#, Jianglong Guo#, Mengsi Liu#, Hongye Wang#, Zhe Li, Weiming Shen, Siying Wang, Huijue Zhu, Xiaoye Liu, Jinhao Li, Yuan Ouyang, Yueze Zhu, Zhen Ye, Shunpeng Xing*, Gang Chen*, Haojie Jin*. Revealing Prognostically Significant Adverse Events Following CAR T-cell Therapy Through a Real-World Data-Driven Approach. EClinicalMedicine. 2025, Dec; (90): 103623. (IF=10.0, 最后通讯)；

2. Wu Yang#, Siying Wang#, Shuyi Ji#, Jian Wang#, Shuo Lian, Zhe Li, Robin A Jansen, Wei Wu, Kongyan Niu, Zhen Sun, Qi Jia, Jiaojiao Zheng, Huijue Zhu, Xuan Deng, Liqin Wang, Zhoulong Fan, Yaoping Shi, Cor Lieftink, Ming Guan, Roderick L Beijersbergen, Wenxin Qin*, Qiang Gao*, René Bernards*, Haojie Jin*. CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma. Proc Natl Acad Sci U S A. 2025 Sep 30;122(39):e2519568122.  (IF=9.2, 最后通讯)；

3. Qi Jia#, Xiaoxiao Sun#, Haoyu Li#, Jianglong Guo, Kongyan Niu, Kui Ming Chan, René Bernards*, Wenxin Qin*, Haojie Jin*. Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges. Gut. 2025 Apr 7;74(5):840-852.  (IF=23, 最后通讯)；

4. Jiaojiao Zheng #, Siying Wang#, Lei Xia#, Zhen Sun#, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen*, Qiang Xia*, Haojie Jin*. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025 Feb 7;10(1):35.  (IF=40.8, 最后通讯)；

5. Hongye Wang#, Zhaorong Wu#, Dan Cui#, Linke Bian, Yaoping Shi, Weiming Shen, Jiufei Zhu, Zhigang Zheng, Qiaoyong Yi, Yixiao Pan, Zhenyu Song, Yantao Li, Haigang Geng, Kangjie Shen, Yuan Li, Zhen Sun, Hexin Yan, Ruidong Hao, Chuanjie Zhang*, Minmin Sun*, Shuangshung Zhang*, Haojie Jin*, Bo Zhai*. Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice. Sci Transl Med. 2025 Jan 22;17(782):eadl6432.  (IF=15.8, 并列通讯，封面论文)；

6. Yaoping Shi*, Dan Cui#, Lei Xia#, Donghua Shi, Guangxin Jing, Siying Wang, Yan Lin, Xiaoyin Tang, Jiachang Chi, Tao Wang, Meng Li, Zicheng Lv, Jiaojiao Zheng, Qi Jia, Wu Yang, Zhen Sun, Fan Yang, Hao Feng, Shengxian Yuan, Weiping Zhou, Wenxin Qin*, Rene Bernards*, Haojie Jin*, Bo Zhai1*. Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial. Signal Transduct Target Ther. 2024 Dec 9;9(1):359. (IF=40.8, 并列通讯)；

7. Sun Z#, Liu M#, Guo J, Wang S, Jin H*. BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024 Jan 17:S0168-8278(24)00046-1. (IF=25.7，最后通讯)

8. Jin H*, Wang L*, Bernards R*. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023, 22: 213-234. (IF=120.1, 第一兼通讯，封面论文);

9. Wang L#,* Jin H#, Jochems F, Wang S, Lieftink C, Martinez IM, De Conti G, Edwards F, de Oliveira RL, Schepers A, Zhou Y, Zheng J, Wu W, Zheng X, Yuan S, Ling J, Jastrzebski K, Santos Dias MD, Song JY, Celie PNH, Yagita H, Yao M, Zhou W, Beijersbergen RL, Qin W*, Bernards R*. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat Cancer. 2022, 3: 1284-1299. (IF=22.7, 并列第一);

10. Jin H#, Shi Y#, Lv Y#, Yuan S#, Ramirez CFA, Lieftink C, Wang L, Wang S, Wang C, Dias MH, Jochems F, Yang Y, Bosma A, Hijmans EM, de Groot MHP, Vegna S, Cui D, Zhou Y, Ling J, Wang H, Guo Y, Zheng X, Isima N, Wu H, Sun C, Beijersbergen RL, Akkari L, Zhou W*, Zhai B*, Qin W*, Bernards R*. EGFR activation limits response of liver cancer to lenvatinib. Nature. 2021, 595: 730-734. (IF=69.5, 第一作者，封面论文);

11. Wang C#, Vegna S#, Jin H#, Benedict B#, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W*, Akkari L*, Bernards R*. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019, 574: 268-272. (IF=43.0, 并列第一);

12. Jin H#, Wang C#, Jin G#, Ruan H, Gu D, Wei L, Wang H, Wang N, Arunachalam E, Zhang Y, Deng X, Yang C, Xiong Y, Feng H, Yao M, Fang J, Gu J, Cong W*, Qin W*. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1. Gastroenterology. 2017, 153: 799-811.e33. (IF=20.7, 第一作者).

科研项目

1. 基金委重点国际合作项目，W2411079，2025/01-2029/12，238万元，在研；

2. 基金委优秀青年科学基金项目，82222047，2023/01-2025/12，200万元，在研；

3. 基金委中欧人才项目，82011530441，2020/09-2022/02，3万元，已结题；

4. 基金委面上项目，82073039，2021/01-2024/12，55万元，已结题；

5. 基金委青年项目，81702838，2018/01-2020/12，20万元，已结题；

6. 上海市优秀学术带头人，22XD1423100，2022/06-2025/05，40万元，已结题；

7. 上海市卫健委医学新技术研究与转化种子计划，2024ZZ1008，2025/01-2027/12，160万元，在研；

8. 上海市卫健委卫生健康学科带头人，2022XD057，2023/01-2025/12，45万元，在研；

9. 上海市青年科技启明星计划，19QA1408200，40万元，已结题；

10. 上海市卫生系统优秀人才培养计划，2018YQ20，2018/07-2021/06，30万元，已结题；

实验室成员

王亚芳，特聘副研究员，中科院上海药物研究所博士

郑娇娇，助理研究员，北京大学博士，助理研究员

王思颖，助理研究员，上海交通大学博士

申伟明，博士后，上海中医药大学博士

姜钰晨，博士后，南昌大学博士

牛孔艳，博士后，中国科学院上海有机化学研究所博士

王   健，博士后，北京大学博士

孔维文，博士后，复旦大学博士

博士研究生：郭江龙，连硕，李哲，杨筱漪

硕士研究生：孙震，徐双蔚，胡培，农桂芳